Fentora (Fentanyl Citrate) Patent Expiration, LOE Window & CMS Spending

Fentora (Fentanyl Citrate) by Teva Pharmaceuticals: FDA Orange Book LOE 2028-06-15, 4 AB generics, $661K 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN021947 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-06-15
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$661K
2024 Medicare Part D Spend$661K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 25.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.